NCT00968981View on ClinicalTrials.gov

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Solid Cancers
Interventions
DRUG

GDC-0449

Daily oral repeating dose

DRUG

GDC-0449

Three times weekly oral repeating dose

DRUG

GDC-0449

Once weekly oral repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY